Most cases of coronavirus disease (COVID-19) are mild \[[@r1]\], making home isolation the standard containment measure for 80% of patients. Guidance on discontinuation of containment measures is hampered by incomplete knowledge on (i) the level and duration of detecting viral material in different patient groups, (ii) the infectious dose and (iii) the role of RT-qPCR as a proxy measure of infectiousness \[[@r2]\]. This uncertainty explains a significant heterogeneity in the current national recommendations on RNA laboratory testing for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as a tool for discontinuing isolation among countries in the European Union and European Economic Area (EU/EEA) \[[@r2]\].

Here, we present a review of currently published literature on the duration of SARS-CoV-2 RNA detection by RT-qPCR in the respiratory tract in various settings and patients groups. We analyse data of consecutive RT-qPCR results in 537 symptomatic patients with mild COVID-19 in home quarantine, collected from 28 February to 6 June 2020 in Rhineland-Palatinate, Germany. With this research, we aim to close a gap in current knowledge on the duration of RNA detection in patients with mild COVID-19 and inform test-based policy of discontinuing home isolation.

Literature review
=================

We searched the PubMed online database on 8 April using the terms 'SARS-CoV-2' AND 'shedding' 'NOT faeces' and identified 85 results. Reviewing these papers and their reference lists yielded 11 studies that had analysed sequential RT-qPCR results in populations of 30 or more COVID-19 patients. One of these 11 studies did not provide any summary statistics on temporality \[[@r3]\] and another had been specifically selected for RNA detection of 30 days or longer \[[@r4]\], leaving nine studies \[[@r5]-[@r13]\] in populations of 32--146 COVID-19 patients for detailed comparison of populations, methods and results ([Table 1](#t1){ref-type="table"}).

###### Reports providing descriptive statistics on duration of SARS-CoV-2 RNA positivity by RT-qPCR with at least 30 subjects and entry in PubMed by 8 April 2020 (n = 9)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref                           Country      Setting      Severity                                Population size   Detection period                               Sampling interval^a^                        Distribution of outcome in population (days)   Time to event analysis   Antivirals, comments                     
  ----------------------------- ------------ ------------ --------------------------------------- ----------------- ---------------------------------------------- ------------------------------------------- ---------------------------------------------- ------------------------ ---------------------- ----------------- ---------------------------------------------------------------------------------------------------------
  \[[@r5]\]                     China        Hospital     53% moderate, 39% severe, 8% critical   137               Symptom onset to two negative results          Regular;\                                   Median: 20.0                                   IQR:\                    37                     None              n = 41 lopinavir/ritonavir; analysis restricted to 137/191 survivors opens potential for selection bias
                                                                                                                                                                   every other day                                                                            17.0--24.0                                                        

  \[[@r7]\]                     China        Hospital     Mild to moderate                        56                Symptom onset to first negative result         Irregular                                   Median: 24.0                                   IQR:\                    42                     None              None
                                                                                                                                                                                                                                                              18.0--31.0                                                        

  \[[@r6]\]                     China        Hospital     94% moderate, 6% severe                 70                Symptom onset to first negative result         Irregular                                   Median: 22.0                                   IQR:\                    No data                None              Focus of study is on re-occurring positives
                                                                                                                                                                                                                                                              19.0--32.0                                                        

  \[[@r8]\]                     China        Hospital     74% moderate, 25% severe, 1% critical   120               Symptom onset to two negative results          Regular;\                                   Median~overall~: 23.0                          IQR:\                    No data                Kaplan--Meier,\   n = 78 lopinavir/ ritonavir and n = 42 no treatment
                                                                                                                                                                   every other day                                                                            18.0--32.0                                      Cox-regression    

  Median~antiviral~: 22.0       IQR:\                                                                                                                                                                                                                                                                                           
                                18.0--29.0                                                                                                                                                                                                                                                                                      

  Median~non-antiviral~: 28.5   IQR:\                                                                                                                                                                                                                                                                                           
                                19.5--38.0                                                                                                                                                                                                                                                                                      

  \[[@r9]\]                     China        Hospital     75% non-ICU\                            32                Symptom onset to first negative result         Irregular                                   Mean~non-ICU~: 15.67                           SD: 6.68\                No data                None              None
                                                          25% ICU                                                                                                                                                                                                                                                               

  Mean~ICU~: 22.25              SD: 3.62                                                                                                                                                                                                                                                                                        

  \[[@r10]\]                    China        Hospital     28% severe                              113               Symptom onset to first negative result         Regular, daily                              Median: 17.0                                   IQR: 13.0--22.0          No data                Kaplan--Meier     n = 55 umifenovir,\
                                                                                                                                                                                                                                                                                                                                n = 19 ribavirin

  \[[@r11]\]                    China        Hospital     83% non- severe;\                       59                From first positive to first negative result   Regular, daily                              Median: 14.0                                   IQR: 10.0--18.0          25                     Kaplan--Meier,\   All patients ribavirin; variation in definition of detection period may explain lower estimates
                                                          17% severe                                                                                                                                                                                                                                          Cox-regression    

  \[[@r12]\]                    China        Hospital     86% moderate; 14% severe                147               Symptom onset to first negative result         Regular,\                                   Median: 17.0                                   IQR: 12.0--21.0          47                     Kaplan--Meier     All patients received antiviral treatment, 'most commonly ribavirin and interferon'
                                                                                                                                                                   every other day                                                                                                                                              

  \[[@r13]\]                    Korea        Outpatient   100% mild                               199               Diagnosis to two negative results              Irregular; every other day to once a week   Mean~overall~: 24.5                            SD: 4.8                  No data                none              53 asymptomatic and 146 symptomatic subjects

  Mean~symptomatic~: 25.2       SD: 4.9                                                                                                                                                                                                                                                                                         

  Mean~asymptomatic~: 22.6      SD: 4.0                                                                                                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ICU: intensive care unit; IQR: interquartile range; Ref: reference; SD: standard deviation.

^a^ Interval of sampling for RT-qPCR.

All nine studies were conducted in East-Asia (eight in China, one in South Korea) and most of them in a hospital setting (n = 8). Substantial proportions of the included patients suffered from severe COVID-19 and received antiviral medication \[[@r5]-[@r13]\]. The methodology and reported estimates were heterogeneous. All but two studies \[[@r11],[@r13]\] used the period from symptom onset to time of first negative RT-qPCR result or time to two consecutive negative RT-qPCR results as outcome of interest. Only half of the studies sampled on a regular basis; daily (n = 2) or every other day (n = 3). Most research, with the exception of one study \[[@r13]\], seemed to use data from irregular (i.e. convenience) sampling. Four studies used survival analysis methods \[[@r8],[@r10]-[@r12]\] but none acknowledged the nature of the data by using interval-censoring \[[@r14],[@r15]\]. This increases the risk of systematic bias and overestimation, particularly in those studies with irregular sampling intervals \[[@r6],[@r7],[@r9]\]. In the seven studies that reported the median duration of RNA detection, the estimates varied from 14 to 24 days. In the remaining two studies, one group reported a mean estimate of 24.5 days. The other study found means of 22.25 and 15.67 days for the intensive care unit (ICU) and non-ICU patient sub-population, respectively. Only one of the nine reviewed studies had looked at COVID-19 patients with mild disease in an outpatient setting; it found viral RNA to be detectable in symptomatic patients for a mean duration of 25.2 days. All nine studies on duration of RNA detection studied small samples, explaining wide measures of spread around the reported estimates. As far as we are aware, there are currently no published data on the duration of RNA positivity in the upper respiratory of patients with mild COVID-19 that could inform a public health assessment of RT-qPCR as a tool for monitoring home isolation.

Retrospective study using routine data from district public health authorities
==============================================================================

Rhineland-Palatinate is one of 16 federal states in Germany and has a population of about 4 million people. Containment of mild COVID-19 cases is managed by 24 district public health authorities (DPHA) responsible for 35 districts. All 24 DPHA received an invitation to retrospectively enter into a EUSurvey database (<https://ec.europa.eu/eusurvey/home/welcome>) information on demographic characteristics and consecutive RT-qPCR results ('positive', 'negative' or 'equivocal') of COVID-19 patients who were in home isolation. No personal identifying information was stored in the online database.

A person was included in the analysis (i) if they were a laboratory-confirmed, RT-qPCR-positive case of COVID-19, (ii) if they were in home isolation between 28 February 2020 (date of first notified COVID-19 case in Rhineland-Palatinate) and 6 June 2020 (end of study period), (iii) if they had tested negative in RT-qPCR in at least one upper respiratory tract sample provided after diagnosis and before 6 June 2020, and (iv) if they had symptoms of COVID-19 before the first (i.e. diagnostic) RT-qPCR test.

For observations with missing information (n = 98), we imputed the date of symptom onset by subtracting the average delay of notification of 5.56, rounded to 6 full days. The latter was calculated from all statutory notifications made by 6 June 2020 that had data on both date of onset and date of statutory notification.

Data were extracted from the online platform on 6 June 2020, imported into Stata, cleaned, and RT-qPCR-results were binarised by recoding 'equivocal' to 'positive'. We used interval-censored survival analysis ('stintreg' command, Stata 15) to estimate survival time, with the left margin of the censoring interval being days between date of onset and last positive swab and the right margin being days between date of onset and first negative swab. Time ratios comparing the median time to RNA negativity in the exposed with that in the unexposed were calculated for several exposure variables. Goodness of fit of different parametric survival models to our data was assessed using the Akaike information criterion \[[@r16]\] and visually by plotting the cumulative hazard function \[[@r17]\] against the Cox--Snell residuals.

Since RT-qPCR analyses were provided by different microbiology laboratories, information on type of RT-qPCR assay, cycle threshold (CT) or raw data on individual CT values were not available. To account for the additional level of variation introduced by the use of different RT-qPCR assays in different microbiology laboratories, we adjusted all regression analyses for clustering by DPHA.

Ethical statement
=================

All data presented were collected in response to the SARS-CoV-2 pandemic and in accordance with the German Infection Protection Act. Institutional review and individual informed consent was not sought.

Duration of RNA positivity
==========================

Sixteen of 24 district public health authorities in Rhineland-Palatinate submitted data for overall 603 patients. On further review, 53 of them were asymptomatic and 13 had missing information on symptoms, leaving 537 symptomatic COVID-19 patients in home isolation for further analysis ([Table 2](#t2){ref-type="table"}).

###### Baseline characteristics of symptomatic COVID-19 patients, Rhineland-Palatinate, Germany, 28 February--6 June 2020 (n = 537)

  Exposure characteristic                                                                 
  ------------------------------------------------------------------ ------- ------------ ------------
                                                                     **n**   **%**        
  Male                                                               233     43.4         
  Female                                                             304     56.6         
  Date of onset unknown^a^                                           98      18.2         
  At least one 'equivocal' laboratory result recoded as 'positive'   17      3.2          
  Immunosuppression^b^                                               7       1.3          
  Treatment before home isolation                                                         
  Inpatient                                                          67      12.5         
  Outpatient                                                         425     79.1         
  Unknown                                                            45      8.4          
  Epidemiological context at time of diagnosis                                            
  Healthcare staff                                                   81      15.1         
  Patient in hospital                                                19      3.5          
  Nursing home resident                                              18      3.4          
  Community^c^                                                       398     74.1         
  Unknown                                                            21      3.9          
                                                                     **n**   **Median**   **IQR**
  Age in years (in five equally sized groups)                                             
  1st                                                                114     26.0         21.0--29.0
  2nd                                                                110     38.0         35.0--41.0
  3rd                                                                108     49.5         46.0--51.5
  4th                                                                105     57.0         55.0--60.0
  5th                                                                100     71.0         64.0--81.0
  RT-qPCR                                                                                 
  Median number of tests per subject until first negative test       537     2.0^d^       2.0--3.0
  Median time to first negative test in days                         537     20.0^e^      16.0--28.0
  Length of censoring intervals^f^ in days                           537     10.0^g^      7.0-15.0

IQR: interquartile range.

^a^ Imputed by date of notification minus delay of notification of 6 days.

^b^ Pregnancy (n = 2), renal transplant and dialysis (n = 2), cancer (n = 2), rheumatoid arthritis (n = 1).

^c^ Not belonging to an institutional transmission context or cluster.

^d^ Minimum--maximum: 2--9 tests.

^e^ Minimum--maximum: 1--68 days.

^f^ Defined as time from last positive to first negative test result in days.

^g^ Minimum--maximum: 1--68 days.

[Figure 1](#f1){ref-type="fig"} displays key statistics of the number of RT-qPCR tests and time periods analysed for this study. A generalised gamma distribution fit our data best ([Supplementary Table S1 and Supplementary Figure](/content/10.2807/1560-7917.ES.2020.25.30.2001292#supplementary_data)). We found that respectively 50%, 25%, and 10% of patients were still positive for SARS-CoV-2 RNA 2, 3 and 4 weeks after the onset of symptoms. At 14 days after onset, the earliest moment to discontinue home isolation currently recommended in Germany \[[@r18]\], 53.5% of COVID-19 patients still had detectable SARS-CoV-2 RNA ([Figure 2](#f2){ref-type="fig"}). Repeating the analysis after exclusion of 17 patients with 'equivocal' RT-qPCR results recoded as 'positive' changed our results only marginally: we found between 0.33 and 1.00% shorter time to SARS-CoV-2 negativity estimates than those displayed in [Figure 2B](#f2){ref-type="fig"}. Comparing the results of the interval-censored analysis ([Figure 2](#f2){ref-type="fig"}) with the distribution of time periods until the first negative test result ([Figure 1B](#f1){ref-type="fig"}) shows that interval censoring gave a ca 5 days shorter estimate for the median RNA detection time (14.96 versus 20 days).

![Number of samples analysed per subject and days until first PCR-negative swab in home-isolated COVID-19 patients, Rhineland-Palatinate, Germany, 2020 (n = 537)](2001292-f1){#f1}

![Duration of SARS-CoV-2-RNA positivity in COVID-19 patients in home isolation, Rhineland-Palatinate, Germany, 2020 (n = 537)](2001292-f2){#f2}

In a model adjusting for all exposure characteristics at once, patients in the oldest age group had 14% shorter median time to PCR negativity than those in the youngest age group (time ratio: 0.86, p = 0.037), while no such differences were found for the remaining age groups. Similarly, nursing home residents had 28% shorter median time to RNA negativity than patients with no specific epidemiological context at time of diagnosis (time ratio: 0.72; p = 0.013). Hospitalisation before home isolation, by contrast, was associated with 26% longer duration of RNA positivity compared with patients in home isolation throughout COVID-19 (time ratio: 1.26; p = 0.049) ([Supplementary Table S2](/content/10.2807/1560-7917.ES.2020.25.30.2001292#supplementary_data)). Using a model adjusting for all exposure characteristics at once to predict time to RNA negativity for given population proportions only marginally changed the results from the unadjusted model ([Figure 2B](#f2){ref-type="fig"}, [Supplementary Table S3](/content/10.2807/1560-7917.ES.2020.25.30.2001292#supplementary_data)).

Contextualisation of findings
=============================

While several countries recommend negative laboratory testing for particular patient groups before discontinuing isolation \[[@r2]\], there is increasing evidence that the period when viral nucleic acid can be detected may exceed the period of infectivity by far. Studying 77 infector--infectee transmission pairs, He at al. found convincing evidence for substantial pre-symptomatic transmission that peaks shortly before the onset of symptoms and then declines until Day 8 after symptom onset \[[@r3]\]. Support for an end of transmissibility around Day 8 after onset of symptoms comes from two independent studies that were not able to propagate virus in cell cultures from RT-qPCR-positive individuals beyond that point in time \[[@r19],[@r20]\]. Against this background, and irrespective of the potential reason for this discrepancy (i.e. higher sensitivity of RT-qPCR or detection of non-replicative RNA remnants), our finding that 78% of patients in home isolation remained RT-qPCR-positive beyond Day 8 after onset of symptoms strongly supports that in patients with mild COVID-19, positive nucleic acid testing results do not allow any conclusions on infectivity. Similarly, respectively 50%, 25% and 10% of all patients would be kept overly long at home when choosing the end of the infectious period on Days 14, 21 and 28 (+/−2 days) after onset of symptoms and hereby cautiously taking into account evidence from one report on prolonged detection of replicative virus in one mild case of COVID-19 \[[@r21]\]. Therefore, RT-qPCR-guided containment leads to additional costs through prolonged periods of isolation and repeated sampling and increases the individual and social burden of the current epidemic.

Compared with published estimates on duration of RNA detection after onset of symptoms, ranging from 14 to 24 days for the median and 15.67 to 24.5 days for the mean, our estimate of the mean of 14.96 days is at the lower end. It is difficult to tell whether this is a result of differences in study population or design, or both. From a methodological point of view, however, we expected that our analysis using interval-censoring (i.e. the interval between the last positive and the first negative swab) would reduce systematic information bias compared with estimates derived from time to first negative swab and would thus lead to shorter estimates of time to RNA negativity than most of the reviewed studies. Accordingly, we found that in our population and setting, the median duration of RNA detection using interval-censoring was ca 5 days shorter than the median time to the first negative test (14.96 versus 20 days).

Conclusion
==========

RT-qPCR testing seems to be of limited value in guiding the duration of home isolation in mild COVID-19. Negative follow-up testing may be useful in providing certainty about non-infectiousness before ending the isolation in settings where onward transmission has particularly detrimental consequences (e.g. healthcare setting) or in patient groups with known risk factors for prolonged viral shedding and the associated risk of infectiousness (e.g. the severely immunosuppressed). For cases where laboratory monitoring is indispensable, knowledge of the RT-qPCR threshold cycle may improve our judgement on whether a positive result indicates infectiousness or not \[[@r20]\]. By contrast, positive follow-up tests correlate poorly with infectiousness. Hence, after the diagnosis of COVID-19 is established, the large proportion of positive results that emerge from RT-qPCR monitoring during the first 4 weeks after onset of symptoms, and that exceed the period of infectiousness by far, do not meaningfully contribute to the anti-epidemic management of mild COVID-19 cases. Instead, they increase the overall cost and social burden of the epidemic without mitigating it. We conclude that for most patients with mild COVID-19, the use of fixed time periods, based on sound estimates of the infectious period, seem more appropriate in guiding the duration of containment measures than laboratory-based approaches. More research on risk groups and factors associated with prolonged infectiousness (e.g. immunosuppression, age and disease severity) is needed to tailor fixed time periods to various settings and groups and ultimately further reduce the use of RT-qPCR in guiding the duration of SARS-CoV-2 containment.
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